Answer
Oct 01, 2025 - 04:44 AM
ZYTIGA is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It is used in combination with prednisone to improve survival and delay disease progression.
